Nexium (Esomeprazole)
esomeprazole magnesium
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Healing of erosive esophagitis (EE) | Adults + pediatrics ≥1 month | Monotherapy | FDA Approved |
| Maintenance of healing of EE | Adults | Monotherapy | FDA Approved |
| Symptomatic GERD | Adults + pediatrics ≥1 year | Monotherapy | FDA Approved |
| Risk reduction of NSAID-associated gastric ulcer | Adults ≥60 yrs and/or history of gastric ulcer | Monotherapy | FDA Approved |
| H. pylori eradication (to reduce duodenal ulcer recurrence) | Adults | Triple therapy (+ amoxicillin + clarithromycin) | FDA Approved |
| Pathological hypersecretory conditions (Zollinger-Ellison syndrome) | Adults | Monotherapy | FDA Approved |
Esomeprazole is the S-enantiomer of omeprazole, approved in the United States in 2001. Compared with racemic omeprazole, esomeprazole undergoes less first-pass hepatic metabolism via CYP2C19, resulting in higher and more consistent systemic bioavailability. This translates to somewhat greater and more predictable acid suppression across the population, including CYP2C19 extensive metabolizers. A notable advantage over omeprazole is the specific FDA-approved indication for NSAID-associated gastric ulcer risk reduction in at-risk adults. Esomeprazole is available by prescription and over-the-counter (20 mg).
Stress ulcer prophylaxis (ICU): Widely used in critically ill patients; supported by guideline recommendations in those with GI bleeding risk factors. Evidence quality: Moderate.
NSAID-induced gastric ulcer healing (active ulcer): While the FDA indication covers risk reduction (prevention), esomeprazole is also used off-label to heal established NSAID-induced ulcers, with clinical trial support. Evidence quality: High.
Functional dyspepsia: Empiric PPI trial recommended by ACG/CAG guidelines as initial management. Evidence quality: Moderate.
Dosing
Adult Dosing — By Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Healing of erosive esophagitis | 20 or 40 mg QD | 20 or 40 mg QD | 40 mg/day | 4 to 8 weeks; if not healed, additional 4 to 8 weeks may be considered Child-Pugh C: max 20 mg QD |
| Maintenance of healing of EE | 20 mg QD | 20 mg QD | 20 mg/day | Controlled studies did not extend beyond 6 months |
| Symptomatic GERD (adults) | 20 mg QD | 20 mg QD | 20 mg/day | 4 weeks; if symptoms unresolved, additional 4 weeks may be considered OTC: 20 mg QD x 14 days; may repeat every 4 months |
| NSAID-associated gastric ulcer risk reduction | 20 or 40 mg QD | 20 or 40 mg QD | 40 mg/day | Up to 6 months; 40 mg did not show additional benefit over 20 mg in clinical trials For patients ≥60 yrs and/or with gastric ulcer history; Child-Pugh C: max 20 mg QD |
| H. pylori eradication — triple therapy | 40 mg QD + amoxicillin 1000 mg BID + clarithromycin 500 mg BID | — | 40 mg/day | 10 days Child-Pugh C: max 20 mg QD; if clarithromycin resistance suspected, consider alternative regimen per ACG guidelines |
| Zollinger-Ellison syndrome / pathological hypersecretion | 40 mg BID | Individualized | 240 mg/day | Titrate to acid output; some patients require divided doses >80 mg/day Child-Pugh C: start 20 mg BID |
Pediatric Dosing
| Indication / Age | Dose | Duration | Notes |
|---|---|---|---|
| Symptomatic GERD (12–17 yrs) | 20 mg QD | 4 weeks | Capsules or oral suspension |
| Symptomatic GERD (1–11 yrs) | 10 mg QD | Up to 8 weeks | Oral suspension only for this age group |
| EE healing (12–17 yrs) | 20 or 40 mg QD | 4–8 weeks | Same dose range as adults |
| EE healing (1–11 yrs, <20 kg) | 10 mg QD | 8 weeks | Oral suspension; weight-based per PI |
| EE healing (1–11 yrs, ≥20 kg) | 10 or 20 mg QD | 8 weeks | Oral suspension; weight-based per PI |
| EE due to acid-mediated GERD (1 month–<1 yr) | Weight-based per PI | Up to 6 weeks | Oral suspension only; safety and efficacy for symptomatic GERD not established in <1 yr |
The key pharmacokinetic advantage of esomeprazole over racemic omeprazole is its reduced susceptibility to CYP2C19-mediated first-pass metabolism. This results in approximately 90% bioavailability at steady state (40 mg) compared with approximately 60% for omeprazole. Consequently, CYP2C19 genotype has a smaller impact on esomeprazole exposure: poor metabolizers show only a 2-fold higher AUC with esomeprazole versus a 5–10-fold higher AUC with omeprazole. In clinical practice, this means more predictable acid suppression across genetically diverse populations. However, head-to-head trials have shown only modest clinical differences in EE healing rates, and many guidelines consider PPIs within the class to be broadly interchangeable for most indications.
Pharmacology
Mechanism of Action
Esomeprazole is the S-enantiomer of omeprazole, a substituted benzimidazole proton pump inhibitor. Like all PPIs, it is a prodrug that concentrates in the acidic secretory canaliculi of gastric parietal cells, where the low pH environment converts it to a sulfenamide that forms an irreversible covalent disulfide bond with cysteine residues on the H+/K+-ATPase (proton pump). This covalent inactivation of the final step of gastric acid secretion provides acid suppression that far outlasts the drug’s plasma half-life, persisting for 24 hours or longer until new pump molecules are synthesized. After 5 days of daily dosing with 40 mg, the percentage of time with intragastric pH above 4 exceeds 68% over a 24-hour period.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Enteric-coated granules; bioavailability ~64% (single 40 mg dose) rising to ~90% at steady state; Tmax ~1.5 h; AUC decreased 43–53% when taken after eating | Higher and more consistent bioavailability than racemic omeprazole due to reduced CYP2C19-mediated first-pass metabolism of the S-isomer; must take ≥1 hour before meals for optimal absorption |
| Distribution | Vd 16–18 L; 97% protein bound; concentrates in parietal cell canaliculi via acid-trapping | Protein binding limits dialysis utility; target-site concentration exceeds plasma levels due to ion trapping in acidic canaliculi |
| Metabolism | Hepatic via CYP2C19 (primary; forms 5-hydroxy metabolite) and CYP3A4 (forms sulfone metabolite); CYP2C19 PM have ~2-fold higher AUC at steady state; S-isomer is relatively resistant to CYP2C19 metabolism compared with R-omeprazole | CYP2C19 polymorphism has less impact on esomeprazole than omeprazole (2-fold vs 5–10-fold AUC difference in PM); CYP2C19 inhibition underlies clopidogrel interaction; AUC increases non-linearly above 40 mg |
| Elimination | t1/2 ~1–1.5 h; ~80% excreted in urine as metabolites; <1% unchanged in urine; remainder in feces | Despite short half-life, irreversible pump inactivation provides ≥24 h acid suppression; severe hepatic impairment (Child-Pugh C) substantially increases exposure — dose reduction required |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 2–11% | Most commonly reported; incidence varies by population and formulation; 8% in adolescents 12–17 yrs |
| Diarrhea | 2–4% | If persistent or severe, consider C. difficile testing |
| Abdominal pain | 1–6% | Evaluate for underlying pathology if persistent; 3% in adolescents |
| Nausea | 1–6% | Higher incidence with IV formulation (6%); generally transient with oral forms |
| Flatulence | 1–10% | Higher incidence with IV formulation (10%); ~1% with oral; related to altered gut flora |
| Constipation | ≥1% | Manage with fiber and hydration |
| Dry mouth | 1–4% | Higher with IV formulation (4%) |
| Dizziness | ≤3% | More common with IV formulation; generally self-limiting |
| Somnolence | 2% (children 1–11 yrs) | Pediatric-specific finding; not reported at similar rates in adults |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| C. difficile-associated diarrhea | Uncommon; risk increases with duration | Any time during or after therapy | Test stool for C. difficile; discontinue PPI if confirmed; initiate directed antibiotic therapy |
| Hypomagnesemia | Rare; mainly with >1 year use | Months to years | Check serum magnesium if symptoms (tetany, arrhythmia, seizures); supplement and consider PPI discontinuation; may lead to secondary hypocalcemia and hypokalemia |
| Bone fractures (hip, wrist, spine) | Observational data; risk with long-term high-dose use | Long-term (≥1 year) | Use lowest effective dose; ensure adequate calcium and vitamin D; FDA class-wide warning |
| Severe cutaneous adverse reactions (SJS, TEN, DRESS, AGEP) | Very rare (postmarketing) | Days to weeks | Discontinue immediately at first signs; can be fatal if untreated |
| Acute interstitial nephritis | Rare (postmarketing) | Weeks to months | Monitor renal function; discontinue PPI |
| Cutaneous or systemic lupus erythematosus | Rare (postmarketing) | Weeks to years | Discontinue PPI; most CLE cases resolve; evaluate for systemic involvement |
| Vitamin B12 deficiency | Rare; with >3 years use | Years | Screen B12 in long-term patients; supplement if deficient |
| Fundic gland polyps | Risk increases with >1 year use | Months to years | Generally benign and reversible; use shortest PPI duration necessary |
| Hypersensitivity (anaphylaxis, angioedema) | Rare (postmarketing) | Any time | Discontinue permanently; contraindicated in benzimidazole hypersensitivity |
The long-term safety profile of esomeprazole is shared across the PPI class. Reassess the need for continued therapy after the initial treatment course (4–8 weeks for uncomplicated GERD). Continuous long-term use is appropriate for Barrett esophagus, severe EE (LA Grade C/D), documented bleeding ulcer history, ZE syndrome, and chronic NSAID co-therapy in high-risk patients. For all others, use the lowest effective dose for the shortest duration, with periodic deprescribing assessments.
Drug Interactions
Esomeprazole shares the same drug interaction profile as racemic omeprazole. It inhibits CYP2C19 (affecting clopidogrel activation and metabolism of CYP2C19 substrates) and elevates gastric pH (impairing absorption of pH-dependent drugs). Esomeprazole is itself metabolized by CYP2C19 and CYP3A4, making it susceptible to strong inducers of these enzymes.
Monitoring
- Symptom Response4–8 weeks
RoutineReassess need for continued PPI. If no erosive disease or high-risk features, consider step-down, on-demand dosing, or H2RA switch. Do not continue indefinitely without clinical indication. - Serum MagnesiumPeriodically in long-term use
Trigger-basedHypomagnesemia reported with ≥3 months PPI use (most cases >1 year). Check if symptoms suggest deficiency (tetany, tremor, arrhythmias). Consider monitoring calcium in those at risk of hypocalcemia. - Vitamin B12Periodically if >3 years use
Trigger-basedChronic acid suppression impairs cyanocobalamin absorption. Screen if symptomatic (fatigue, neuropathy, macrocytosis). - Bone DensityPer osteoporosis guidelines
Trigger-basedFDA class-wide warning; greatest risk with long-term high-dose use. Ensure adequate calcium and vitamin D. - Chromogranin AStop PPI ≥14 days before testing
Trigger-basedPPIs elevate CgA levels, causing false-positive results for neuroendocrine tumors. - Renal FunctionIf new symptoms on long-term use
Trigger-basedAcute interstitial nephritis is a rare PPI class effect; evaluate creatinine if new renal symptoms.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to substituted benzimidazoles or any excipient: Includes esomeprazole, omeprazole, lansoprazole, pantoprazole, rabeprazole, and dexlansoprazole. Reactions include anaphylaxis, angioedema, bronchospasm, acute interstitial nephritis, and urticaria.
- Rilpivirine-containing products: Elevated gastric pH drastically reduces rilpivirine absorption, risking HIV treatment failure and resistance.
Relative Contraindications (Specialist Input Recommended)
- Concurrent clopidogrel: FDA PI states to avoid concomitant use. If acid suppression essential, consider pantoprazole or H2RA.
- Severe hepatic impairment (Child-Pugh C): Exposure substantially increased; max 20 mg QD for most indications; 20 mg BID starting dose for ZE syndrome.
Use with Caution
- Long-term use without clear indication: Reassess regularly. Risk of C. difficile, hypomagnesemia, B12 deficiency, fractures, fundic gland polyps, and severe cutaneous reactions.
- Patients at osteoporosis risk: Use lowest effective dose; ensure calcium/vitamin D supplementation.
- Suspected gastric malignancy: Symptomatic improvement does not exclude malignancy; complete endoscopic evaluation before long-term therapy.
The FDA issued class-wide warnings for PPIs regarding (1) possible increased risk of hip, wrist, and spine fractures with long-term, high-dose use (2010/2011) and (2) severe cutaneous adverse reactions including SJS, TEN, DRESS, and AGEP (2017 update for esomeprazole). Discontinue esomeprazole immediately at the first signs or symptoms of severe skin reactions. Use the lowest dose and shortest duration appropriate to the clinical condition.
Patient Counselling
Purpose of Therapy
Esomeprazole reduces stomach acid to help heal ulcers, relieve heartburn, protect the esophagus from acid damage, and prevent stomach ulcers caused by anti-inflammatory medications. It works best when taken consistently before meals.
How to Take
Take esomeprazole at least one hour before a meal, preferably in the morning. Swallow the capsule whole with water. If you cannot swallow the capsule, open it and sprinkle the granules on a tablespoon of applesauce, then swallow immediately without chewing. For the oral suspension, mix the packet contents with water as directed and drink within 30 minutes.
Sources
- NEXIUM (esomeprazole magnesium) delayed-release capsules / for delayed-release oral suspension. Full Prescribing Information. AstraZeneca. Revised 2023. FDA Label (2023)Primary reference for all oral dosing, indications, adverse reactions, drug interactions, and pharmacokinetic data.
- NEXIUM (esomeprazole magnesium). DailyMed. Updated December 2025. DailyMedMost current version of the branded label with updated dosing table and safety information.
- Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96(3):656-665. doi:10.1111/j.1572-0241.2001.03600.xHead-to-head trial establishing esomeprazole 40 mg superiority over omeprazole 20 mg for erosive esophagitis healing.
- Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients. Aliment Pharmacol Ther. 2000;14(10):1249-1258. doi:10.1046/j.1365-2036.2000.00844.xEarly comparative trial showing improved healing rates with esomeprazole vs omeprazole in severe EE.
- Goldstein JL, Johanson JF, Suchower LJ, et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy. Am J Gastroenterol. 2005;100(12):2650-2657. doi:10.1111/j.1572-0241.2005.00328.xKey trial supporting the NSAID-associated gastric ulcer prevention indication.
- Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101(4):701-710. doi:10.1111/j.1572-0241.2006.00499.xEstablished esomeprazole 20 and 40 mg for NSAID gastroprotection in at-risk populations.
- Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538Current ACG GERD guideline with PPI dosing, step-down, and long-term management recommendations.
- Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-239. doi:10.1038/ajg.2016.563ACG guideline recommending PPI-based triple or quadruple therapy for H. pylori eradication.
- Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors. Can Fam Physician. 2017;63(5):354-364. PMID:28500192Evidence-based deprescribing guideline for PPI reduction or cessation in patients without high-risk indications.
- Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(Suppl 2):2-8. doi:10.1111/j.1365-2036.2006.02943.xAuthoritative review of irreversible H+/K+-ATPase inhibition and the pharmacologic basis for PPI efficacy.
- Dean L, Kane M. Omeprazole Therapy and CYP2C19 Genotype. In: Pratt VM, et al., editors. Medical Genetics Summaries. Bethesda (MD): NCBI; 2021. NBK100895CPIC/DPWG pharmacogenomic review covering CYP2C19 allele-specific effects on both omeprazole and esomeprazole.
- FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. FDA. Revised March 2011. FDA.govFDA class-wide safety communication on PPI-associated fracture risk.
- FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs. FDA. Revised March 2011. FDA.govFDA safety communication on PPI-associated hypomagnesemia.